ToxCast Endpoints
For more information regarding the endpoints, refer to the 'ToxCast Endpoints' file on the DOWNLOAD page.

No ToxCast endpoints for intended target type: RNA

ToxCast Endpoints for intended target type: Protein
Assay NameTissueTarget Gene IDTarget HGNC SymbolTarget UniProt IDResponseAC50 value
CCTE_Deisenroth_5AR_NBTE_acceptorKidneyActivatory0.60 μM
STM_H9_OrnCyssISnorm_ratioInhibitory0.08 μM
CCTE_GLTED_hTTR_0.125uM7276TTRLoss32.20 μM
ATG_AP_1_CISLiver3725|2353JUN|FOSP01100|P05412Activatory2.75 μM
ATG_NRF2_ARE_CISLiver4780NFE2L2Q16236Activatory0.13 μM
ATG_p53_CISLiver7157TP53P04637Inhibitory1.56 μM
NVS_MP_hPBRIntestinal706TSPOP30536Loss0.44 μM
NVS_NR_hTRa_Antagonist7067THRAP10827Loss38.33 μM
CCTE_GLTED_hDIO21734DIO2Loss153.82 μM
CCTE_GLTED_hDIO31735DIO3Loss156.55 μM
TOX21_AR_BLA_Antagonist_ratioKidney367ARP10275Loss0.14 μM
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881Breast367ARP10275Loss0.13 μM
TOX21_Aromatase_LUC_AntagonistBreast1588CYP19A1P11511Loss0.15 μM
TOX21_ERa_BLA_Antagonist_ratioKidney2099ESR1P03372Loss0.10 μM
TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2Breast2099ESR1P03372Loss0.19 μM
TOX21_GR_BLA_Agonist_ratioCervix2908NR3C1P04150Gain65.43 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881Breast367ARP10275Loss0.13 μM
TOX21_AP1_BLA_Agonist_ratioCervix3725|4029FOS|JUN|JUNP05412|P01100|P05412Gain38.19 μM
TOX21_CAR_LUC_AntagonistLiver9970NR1I3Q14994Loss45.94 μM
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2Breast2099ESR1P03372Loss0.14 μM
TOX21_ERR_LUC_AntagonistKidney2101ESRRAP11474Loss0.11 μM
TOX21_PGC_ERR_LUC_AntagonistKidney2101ESRRAP11474Loss0.13 μM
TOX21_ERb_BLA_Antagonist_ratioKidney2100ESR2Q92731Loss0.31 μM
TOX21_PR_BLA_Antagonist_ratioKidney5241PGRP06401Loss44.56 μM
TOX21_PXR_LUC_AgonistLiver8856NR1I2O75469Gain1.46 μM
TOX21_p450_CYP3A4_Antagonist1576CYP3A4P08684Loss1.17 μM
TOX21_p450_CYP1A2_Antagonist1544CYP1A2P05177Loss36.27 μM
TOX21_AChE_ms_Antagonist43ACHEP22303Loss74.86 μM
TOX21_hERG_U2OS_AntagonistBone3757KCNH2Q12809Loss2.77 μM
TOX21_AR_BLA_Antagonist_ratioKidney367ARP10275Loss0.14 μM
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881Breast367ARP10275Loss0.13 μM
TOX21_Aromatase_LUC_AntagonistBreast1588CYP19A1P11511Loss0.15 μM
TOX21_ERa_BLA_Antagonist_ratioKidney2099ESR1P03372Loss0.09 μM
TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2Breast2099ESR1P03372Loss0.22 μM
TOX21_GR_BLA_Antagonist_ratioCervix2908NR3C1P04150Loss38.32 μM
TOX21_VDR_BLA_Antagonist_ratioKidney7421|1591CYP24A1|VDRQ07973|P11473Loss39.08 μM
TOX21_VDR_BLA_Antagonist_ch1KidneyGain35.81 μM
TOX21_VDR_BLA_Antagonist_ch2KidneyLoss62.82 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881Breast367ARP10275Loss0.13 μM
TOX21_AP1_BLA_Agonist_ratioCervix3725|4029FOS|JUN|JUNP05412|P01100|P05412Gain55.39 μM
TOX21_CAR_LUC_AntagonistLiver9970NR1I3Q14994Loss53.74 μM
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2Breast2099ESR1P03372Loss0.17 μM
TOX21_ERR_LUC_AntagonistKidney2101ESRRAP11474Loss0.11 μM
TOX21_PGC_ERR_LUC_AntagonistKidney2101ESRRAP11474Loss0.09 μM
TOX21_ERb_BLA_Antagonist_ratioKidney2100ESR2Q92731Loss0.33 μM
TOX21_PR_BLA_Antagonist_ratioKidney5241PGRP06401Loss45.92 μM
TOX21_PXR_LUC_AgonistLiver8856NR1I2O75469Gain1.38 μM
TOX21_p450_CYP3A4_Antagonist1576CYP3A4P08684Loss1.45 μM
TOX21_AChE_ms_Antagonist43ACHEP22303Loss53.44 μM
TOX21_hERG_U2OS_AntagonistBone3757KCNH2Q12809Loss3.01 μM

No ToxCast endpoints for intended target type: Molecular Messengers

ToxCast Endpoints for intended target type: Pathway
Assay NameTissueTarget Gene IDTarget HGNC SymbolTarget UniProt IDResponseAC50 value
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_AntagonistBone367ARP10275Loss0.75 μM
ACEA_ER_80hrBreast2099ESR1P03372Gain0.04 μM
OT_AR_ARSRC1_0960Kidney6714|367AR|SRCP12931|P10275Gain0.55 μM
OT_ER_ERaERa_1440Kidney2099ESR1P03372Gain62.31 μM
OT_ER_ERaERb_0480Kidney2100|2099ESR2|ESR1Q92731|P03372Gain71.27 μM
OT_ER_ERbERb_0480Kidney2100ESR2Q92731Gain55.07 μM
OT_ER_ERbERb_1440Kidney2100ESR2Q92731Gain76.39 μM
OT_FXR_FXRSRC1_0480Kidney6714|9971NR1H4|SRCP12931|Q96RI1Gain1.36 μM
OT_NURR1_NURR1RXRa_0480Kidney4929|6256NR4A2|RXRAP19793|P43354Gain0.60 μM
OT_NURR1_NURR1RXRa_1440Kidney4929|6256NR4A2|RXRAP19793|P43354Gain0.77 μM
ACEA_AR_antagonist_80hrProstate367ARP10275Loss0.04 μM
TOX21_ERa_BLA_Agonist_ch1KidneyLoss65.92 μM
TOX21_GR_BLA_Agonist_ch1CervixLoss37.66 μM
TOX21_ARE_BLA_Agonist_ch2LiverGain0.09 μM
TOX21_ARE_BLA_Agonist_ratioLiver4780NFE2L2Q16236Gain0.11 μM
TOX21_p53_BLA_p1_ch1IntestinalLoss39.62 μM
TOX21_p53_BLA_p1_ratioIntestinal7157TP53P04637Gain48.26 μM
TOX21_ERa_BLA_Antagonist_ch1KidneyGain0.15 μM
TOX21_ERa_BLA_Antagonist_ch2KidneyLoss0.09 μM
TOX21_AR_BLA_Antagonist_ch2KidneyLoss0.17 μM
TOX21_p53_BLA_p4_ch1IntestinalLoss35.85 μM
TOX21_p53_BLA_p4_ratioIntestinal7157TP53P04637Gain44.49 μM
TOX21_NFkB_BLA_agonist_ch1CervixLoss71.84 μM
TOX21_AP1_BLA_Agonist_ch1CervixLoss49.26 μM
TOX21_AP1_BLA_Agonist_ch2CervixGain38.19 μM
TOX21_TSHR_HTRF_Agonist_ch2KidneyGain57.18 μM
TOX21_TSHR_HTRF_Antagonist_ch1KidneyGain42.21 μM
TOX21_TSHR_wt_HTRF_Agonist_ch2KidneyGain57.86 μM
TOX21_TSHR_wt_HTRF_Agonist_ratioKidney7253TSHRGain45.94 μM
TOX21_HRE_BLA_Agonist_ch1CervixLoss44.75 μM
TOX21_ERb_BLA_Antagonist_ch2KidneyLoss0.53 μM
TOX21_PR_BLA_Antagonist_ch2KidneyLoss56.92 μM
TOX21_ERa_BLA_Agonist_ch1KidneyLoss66.56 μM
TOX21_GR_BLA_Agonist_ch1CervixLoss57.01 μM
TOX21_ARE_BLA_Agonist_ratioLiver4780NFE2L2Q16236Gain0.20 μM
TOX21_HSE_BLA_Agonist_ch1CervixLoss53.85 μM
TOX21_HSE_BLA_Agonist_ratioCervix3297HSF1Q00613Gain61.26 μM
TOX21_p53_BLA_p1_ratioIntestinal7157TP53P04637Gain65.68 μM
TOX21_ERa_BLA_Antagonist_ch1KidneyGain0.06 μM
TOX21_ERa_BLA_Antagonist_ch2KidneyLoss0.13 μM
TOX21_FXR_BLA_Antagonist_ch1KidneyGain0.64 μM
TOX21_GR_BLA_Antagonist_ch2CervixLoss33.34 μM
TOX21_PPARd_BLA_Antagonist_ch2KidneyLoss59.85 μM
TOX21_AR_BLA_Antagonist_ch1KidneyGain0.43 μM
TOX21_AR_BLA_Antagonist_ch2KidneyLoss0.13 μM
TOX21_p53_BLA_p2_ch1IntestinalLoss34.35 μM
TOX21_p53_BLA_p3_ch1IntestinalLoss33.84 μM
TOX21_p53_BLA_p4_ch1IntestinalLoss40.97 μM
TOX21_p53_BLA_p4_ratioIntestinal7157TP53P04637Gain35.77 μM
TOX21_AP1_BLA_Agonist_ch1CervixLoss56.90 μM
TOX21_AP1_BLA_Agonist_ch2CervixGain53.71 μM
TOX21_TSHR_HTRF_Antagonist_ch1KidneyGain55.06 μM
TOX21_TSHR_wt_HTRF_Agonist_ch2KidneyGain54.47 μM
TOX21_TSHR_wt_HTRF_Agonist_ratioKidney7253TSHRGain46.08 μM
TOX21_ERb_BLA_Antagonist_ch2KidneyLoss0.23 μM
TOX21_PR_BLA_Antagonist_ch2KidneyLoss64.71 μM

ToxCast Endpoints for intended target type: Cellular
Assay NameTissueResponseAC50 value
CCTE_Harrill_HTTr_Viability_MCF7BreastGain0.16 μM
CCTE_Harrill_HTTr_Apoptosis_MCF7BreastGain0.05 μM
STM_H9_NormalizedViabilityLoss0.12 μM
ACEA_AR_agonist_AUC_viabilityProstateLoss0.01 μM
ACEA_AR_antagonist_AUC_viabilityProstateLoss0.01 μM
CCTE_Harrill_HTTr_Viability_MCF7BreastGain0.21 μM
CCTE_Harrill_HTTr_Apoptosis_MCF7BreastGain0.10 μM
TOX21_AR_BLA_Antagonist_viabilityKidneyLoss0.68 μM
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viabilityBreastLoss1.09 μM
TOX21_Aromatase_LUC_Antagonist_viabilityBreastLoss1.06 μM
TOX21_MMP_fitcLiverGain2.40 μM
TOX21_p53_BLA_p1_viabilityIntestinalLoss64.38 μM
TOX21_PPARd_BLA_Agonist_viabilityKidneyLoss1.18 μM
TOX21_p53_BLA_p2_viabilityIntestinalLoss45.94 μM
TOX21_p53_BLA_p3_viabilityIntestinalLoss36.82 μM
TOX21_p53_BLA_p4_viabilityIntestinalLoss58.16 μM
TOX21_p53_BLA_p5_viabilityIntestinalLoss63.23 μM
TOX21_VDR_BLA_Agonist_viabilityKidneyLoss0.89 μM
TOX21_NFkB_BLA_agonist_viabilityCervixLoss62.81 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viabilityBreastLoss0.98 μM
TOX21_RXR_BLA_Agonist_viabilityKidneyLoss45.56 μM
TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viabilityBreastLoss0.30 μM
TOX21_AP1_BLA_Agonist_viabilityCervixLoss59.40 μM
TOX21_CAR_LUC_Agonist_viabilityLiverLoss1.78 μM
TOX21_CAR_LUC_Antagonist_viabilityLiverLoss1.83 μM
TOX21_ERR_LUC_viabilityKidneyLoss0.26 μM
TOX21_HDAC_LUC_Antagonist_viabilityColonLoss45.94 μM
TOX21_PGC_ERR_LUC_viabilityKidneyLoss0.30 μM
TOX21_RT_HEK293_GLO_32hr_viabilityKidneyLoss1.75 μM
TOX21_RT_HEK293_GLO_40hr_viabilityKidneyLoss0.86 μM
TOX21_RT_HEPG2_GLO_16hr_viabilityLiverLoss33.01 μM
TOX21_RT_HEPG2_GLO_32hr_viabilityLiverLoss35.15 μM
TOX21_RT_HEPG2_GLO_40hr_viabilityLiverLoss39.90 μM
TOX21_PR_BLA_Agonist_viabilityKidneyLoss78.39 μM
TOX21_PR_BLA_Antagonist_viabilityKidneyLoss74.15 μM
TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viabilityBreastLoss2.11 μM
TOX21_RT_HEPG2_GLO_24hr_viabilityLiverLoss32.19 μM
TOX21_PXR_LUC_Agonist_viabilityLiverLoss1.78 μM
TOX21_SBE_BLA_Antagonist_viabilityKidneyLoss34.01 μM
TOX21_SBE_BLA_Agonist_viabilityKidneyLoss39.66 μM
TOX21_AR_BLA_Antagonist_viabilityKidneyLoss0.77 μM
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viabilityBreastLoss1.38 μM
TOX21_Aromatase_LUC_Antagonist_viabilityBreastLoss1.79 μM
TOX21_MMP_fitcLiverGain2.37 μM
TOX21_AhR_LUC_Agonist_viabilityLiverLoss2.63 μM
TOX21_FXR_BLA_agonist_viabilityKidneyLoss38.30 μM
TOX21_p53_BLA_p2_viabilityIntestinalLoss38.30 μM
TOX21_p53_BLA_p3_viabilityIntestinalLoss59.65 μM
TOX21_p53_BLA_p4_viabilityIntestinalLoss67.53 μM
TOX21_p53_BLA_p5_viabilityIntestinalLoss60.82 μM
TOX21_ESRE_BLA_Agonist_viabilityCervixLoss38.32 μM
TOX21_NFkB_BLA_agonist_viabilityCervixLoss61.85 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viabilityBreastLoss0.69 μM
TOX21_RXR_BLA_Agonist_viabilityKidneyLoss49.57 μM
TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viabilityBreastLoss0.30 μM
TOX21_CAR_LUC_Agonist_viabilityLiverLoss2.11 μM
TOX21_CAR_LUC_Antagonist_viabilityLiverLoss1.56 μM
TOX21_ERR_LUC_viabilityKidneyLoss0.21 μM
TOX21_HRE_BLA_Agonist_viabilityCervixLoss38.32 μM
TOX21_PGC_ERR_LUC_viabilityKidneyLoss0.18 μM
TOX21_RT_HEK293_GLO_32hr_viabilityKidneyLoss2.41 μM
TOX21_RT_HEK293_GLO_40hr_viabilityKidneyLoss0.95 μM
TOX21_PR_BLA_Agonist_viabilityKidneyLoss81.06 μM
TOX21_PR_BLA_Antagonist_viabilityKidneyLoss74.98 μM
TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viabilityBreastLoss2.01 μM
TOX21_PXR_LUC_Agonist_viabilityLiverLoss0.99 μM
TOX21_SBE_BLA_Antagonist_viabilityKidneyLoss35.49 μM
TOX21_SBE_BLA_Agonist_viabilityKidneyLoss35.91 μM

No ToxCast endpoints for intended target type: Extracellular
DISCLAIMER

TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.